HEMATOLOGICAL MALIGNANCIES
Clinical trials for HEMATOLOGICAL MALIGNANCIES explained in plain language.
Never miss a new study
Get alerted when new HEMATOLOGICAL MALIGNANCIES trials appear
Sign up with your email to follow new studies for HEMATOLOGICAL MALIGNANCIES, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Supercharged immune cells take on tough T-Cell cancers
Disease control Not yet recruitingThis Phase 2 trial tests a new treatment for aggressive T-cell blood cancers. Patients receive specially engineered natural killer (NK) cells from donated cord blood, along with chemotherapy, to try to keep the cancer in remission. The study will enroll 70 adults aged 18-80 whose…
Matched conditions: HEMATOLOGICAL MALIGNANCIES
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 23, 2026 20:48 UTC
-
MRNA technology takes on Hard-to-Treat multiple myeloma
Disease control Not yet recruitingThis early-phase trial tests a new mRNA-based drug called WGb-0302 in 20 adults with recurrent or treatment-resistant multiple myeloma and other blood cancers. The therapy uses lipid nanoparticles to deliver mRNA that targets BCMA, a protein on cancer cells. The main goals are to…
Matched conditions: HEMATOLOGICAL MALIGNANCIES
Phase: EARLY_PHASE1 • Sponsor: Sichuan University • Aim: Disease control
Last updated Jun 23, 2026 20:46 UTC
-
New drug aims to boost red blood cells after transplant
Disease control Not yet recruitingThis study compares luspatercept to epoetin for patients with blood cancers who have poor red blood cell recovery after a stem cell transplant. About 90 adults will receive either drug every three weeks for 24 weeks. The goal is to see which treatment better reduces the need for …
Matched conditions: HEMATOLOGICAL MALIGNANCIES
Phase: PHASE2, PHASE3 • Sponsor: Nanfang Hospital, Southern Medical University • Aim: Disease control
Last updated Jun 23, 2026 11:58 UTC
-
New drug aims to stop anemia after stem cell transplant
Disease control Not yet recruitingThis study tests whether the drug luspatercept can prevent poor red blood cell recovery after a stem cell transplant in people with blood cancers and moderate to severe myelofibrosis. About 196 participants will receive either luspatercept or standard supportive care. The goal is…
Matched conditions: HEMATOLOGICAL MALIGNANCIES
Phase: PHASE2, PHASE3 • Sponsor: Nanfang Hospital, Southern Medical University • Aim: Disease control
Last updated Jun 22, 2026 11:55 UTC
-
Can a drug combo fix platelet transfusion failure in blood cancer?
Disease control Not yet recruitingThis study tests whether acalabrutinib (a BTK inhibitor) alone or with bortezomib can lower harmful HLA antibodies that cause platelet transfusions to fail in blood cancer patients. About 42 adults with platelet transfusion refractoriness and high antibody levels will receive the…
Matched conditions: HEMATOLOGICAL MALIGNANCIES
Phase: PHASE3 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 22, 2026 11:55 UTC
-
In-body CAR-T shot aims to revolutionize blood cancer treatment
Disease control Not yet recruitingThis early-phase study tests a new approach to CAR-T therapy for B-cell blood cancers like lymphoma and leukemia. Instead of removing and modifying cells in a lab, the treatment delivers mRNA wrapped in fat particles directly into the body to reprogram immune cells. The goal is t…
Matched conditions: HEMATOLOGICAL MALIGNANCIES
Phase: EARLY_PHASE1 • Sponsor: The 923rd Hospital of Joint Logistics Support Force of People's Liberation Army • Aim: Disease control
Last updated Jun 17, 2026 12:06 UTC
-
New stem cell transplant could help more blood cancer patients find a donor
Disease control Not yet recruitingThis study tests a new way to do stem cell transplants for adults with high-risk blood cancers who don't have a fully matched donor. Doctors will use stem cells from a half-matched (haploidentical) donor and remove certain immune cells to try to prevent severe graft-versus-host d…
Matched conditions: HEMATOLOGICAL MALIGNANCIES
Phase: NA • Sponsor: Miltenyi Biomedicine GmbH • Aim: Disease control
Last updated Jun 15, 2026 18:56 UTC
-
New study to reveal hidden immune effects of common leukemia drug
Knowledge-focused Not yet recruitingThis study will observe 10 adults with acute myeloid leukemia who are receiving the drug gilteritinib after a stem cell transplant. Researchers want to understand how gilteritinib affects the behavior, metabolism, and function of immune cells like T-cells and monocytes. The goal …
Matched conditions: HEMATOLOGICAL MALIGNANCIES
Phase: NA • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jun 23, 2026 11:54 UTC
-
French study to probe alternative medicine use in blood cancer patients
Knowledge-focused Not yet recruitingThis study looks at how people with blood cancers (like leukemia, lymphoma, or myeloma) in France use complementary and alternative medicines (CAM), such as acupuncture or herbal remedies. Researchers will survey 85 patients and interview some to understand why they use these the…
Matched conditions: HEMATOLOGICAL MALIGNANCIES
Phase: NA • Sponsor: University Hospital, Limoges • Aim: Knowledge-focused
Last updated Jun 15, 2026 19:05 UTC
-
AI to predict heart damage from cancer treatments in major european study
Knowledge-focused Not yet recruitingThis study will collect data from up to 10,000 cancer patients across Europe to create better tools for predicting heart damage caused by certain cancer treatments. Researchers will use artificial intelligence alongside standard methods to develop risk scores that doctors can use…
Matched conditions: HEMATOLOGICAL MALIGNANCIES
Sponsor: University Hospital, Caen • Aim: Knowledge-focused
Last updated Jun 15, 2026 18:56 UTC